Scotiabank analyst Louise Chen raised the firm’s price target on Merck (MRK) to $120 from $105 and keeps an Outperform rating on the shares. The firm notes the company’s execution was better than anticipated, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Is AstraZeneca’s Stock (AZN) a Good Investment Right Now?
- Top drug regulator Richard Pazdur preparing to exit FDA, STAT News reports
- Merck price target raised to $120 from $92 at Goldman Sachs
- Vaccine committee considers changes to childhood schedule, NY Times reports
- Midday Fly By: Nvidia invests in Synopsys, U.S. strikes pharma deal with UK